Atrium Therapeutics

IPO

Atrium Therapeutics is a biotech company in United States, founded in 2025. It has raised $270.0M across 1 round, most recently a $270.0M Venture Round in February 2026.

Paving a New Path for Precision Cardiology

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$270.0M
Last Round
$270.0M Venture RoundFeb 2026
Rounds
1
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

Atrium Therapeutics is a San Diego-based precision cardiology biotech that began trading on Nasdaq under ticker RNA on February 27, 2026, established as an independent spinoff in connection with Novartis AG's acquisition of Avidity Biosciences. The company develops RNA medicines for rare, life-threatening genetic cardiomyopathies, using a targeted delivery platform that couples the tissue selectivity of monoclonal antibodies and other ligands with siRNA payloads delivered directly to heart tissue. Its two lead development candidates are ATR-1072 for PRKAG2 syndrome and ATR-1086 for phospholamban (PLN) cardiomyopathy, alongside two undisclosed research-stage targets. Atrium launched with approximately $270 million in cash and cash equivalents and is led by President and CEO Kathleen Gallagher.

Summary

It lists 1–10 employees. It has raised $270.0M in total across 1 round, most recently a $270.0M Venture Round in Feb 2026.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Venture RoundVenture RoundFeb 2026
$270.0M

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atrium Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/atrium-therapeutics"><img src="https://indexed.vc/api/badge/company/atrium-therapeutics" alt="Atrium Therapeutics on Indexed.vc" width="260" height="76" /></a>